- Altamira Therapeutics ( NASDAQ: CYTO ) on Tuesday announced peer-reviewed publication of data that showed that its RNA delivery platform was an effective treatment for abdominal aortic aneurysm (AAA) in rodents.
- The peer-reviewed article was titled "Peptide-siRNA nanoparticles targeting NF-?B p50 mitigate experimental abdominal aortic aneurysm (AAA) progression and rupture" and was published in the journal Biomaterials Advances .
- CYTO stock had gained 9.5% to $0.53 in morning trading.
- The article, which was co-authored by CYTO's chief scientific officer, covered a preclinical study conducted by a research group at Washington University that found that CYTO's peptide-based OligoPhore delivery platform using siRNA was effective in mitigating AAA progression and rupture in a rodent model study.
- AAA is a condition characterized by the enlargement or swelling of the aorta - the main blood vessel that delivers blood to the body - at the abdomen. It can be life threatening if the swelling bursts.
For further details see:
Altamira gains on peer-reviewed preclinical data publication for its RNA delivery platform